NCT04625270Phase 2Active not recruiting

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Study sponsor: Verastem, Inc. · VSTM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-11-15Actual
Enrollment · participants225Estimated
Source updated2025-01-29Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview